Compare NWN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | NVCR |
|---|---|---|
| Founded | 1859 | 2000 |
| Country | United States | Switzerland |
| Employees | 1619 | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2018 | 2015 |
| Metric | NWN | NVCR |
|---|---|---|
| Price | $50.83 | $15.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $54.33 | $28.08 |
| AVG Volume (30 Days) | 244.6K | ★ 1.5M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ 36.45 | 21.79 |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,289,363,000.00 | $655,353,000.00 |
| Revenue This Year | $11.37 | $7.72 |
| Revenue Next Year | $4.46 | $6.74 |
| P/E Ratio | $21.67 | ★ N/A |
| Revenue Growth | ★ 11.83 | 8.28 |
| 52 Week Low | $39.29 | $9.82 |
| 52 Week High | $55.99 | $18.92 |
| Indicator | NWN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 44.45 |
| Support Level | $48.32 | $14.85 |
| Resistance Level | $53.92 | $15.19 |
| Average True Range (ATR) | 1.14 | 0.87 |
| MACD | 0.27 | -0.33 |
| Stochastic Oscillator | 78.30 | 34.89 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.